BioMedNewsBreaks Archive - Page 110 of 214

TuesdaySep 27, 2022 1:52 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Collaborates with EVERSANA(R) to Bring BEATdiabetes Solution to Market

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a preliminary agreement with EVERSANA(R), a pioneer of next-gen commercial services to the global life sciences industry. The agreement covers the U.S. and all global sales and marketing of Nemaura’s diabetes management program, BEATdiabetes, which is based on Nemaura’s noninvasive glucose monitoring solution, proBEAT(TM). Nemaura and EVERSANA will collaborate to develop the optimal launch strategy for large-scale adoption of the program, including franchising and direct sales to self-insured corporate clients and health…

TuesdaySep 27, 2022 11:39 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering and intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may also be used for acquisitions of complementary businesses, technologies or other assets. As a result of the offering, the company’s…

TuesdaySep 27, 2022 10:47 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual investors; the agreements outline an investment in the company of approximately $3.67 million. According to the announcement, the various shares purchase agreements outline plans for a private offering of $3.67 million earmarked to purchase 36.7 million of the company’s Class A shares; the company anticipates that the investment will be complete this month. “This equity investment is important to the company’s operations as well as research and…

MondaySep 26, 2022 11:34 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase 2b proof-of-concept data, which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren’s disease in its early stages, as well as plans for two additional phase 2 studies, one in frozen shoulder, which has recently commenced, and the other in post-operative cognitive…

MondaySep 26, 2022 10:55 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, expands the IP related to the company’s development of TRP-8803. “Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs,” said Jim Gilligan, chief executive officer of Tryp…

FridaySep 23, 2022 2:40 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as well as throughout the previous fiscal year, we have made important advancements in our pharmaceutical drug development programs, including expanding our phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa to include adolescents, and initiating a research collaboration agreement to further screen cannabinoid analogs for potential therapeutic uses. As announced on Sept. 8, 2022, we have…

FridaySep 23, 2022 1:28 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its previously disclosed common share subscription agreement with a third-party investor dated Aug. 26, 2022, and the subsequent filing of a shelf prospectus supplement in connection therewith on Sept. 7, 2022, it has closed the second tranche of the first issuance under the subscription agreement. Mydecine also announced the appointment of John Ross as its chief financial officer.…

FridaySep 23, 2022 12:12 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the following event at 1:00 p.m. ET on Wednesday, Sept. 28, 2022: Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (“GBM”). As part of the virtual event, Climaco will discuss the company’s ongoing potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. Interested parties should visit https://ibn.fm/ktCnW…

ThursdaySep 22, 2022 2:15 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002

Odyssey Health (OTC: ODYY) announced in August the completion and findings of cohort I of the multiday ascending dosing (“MAD”) stage of its ongoing phase I clinical trial showing that PRV-002 was safe and well tolerated. A recent article reads: “Additionally, pharmacokinetic (‘PK’) analysis of the data from the first cohort provided new information that supports the hypothesis that more drug is getting to the brain itself than the circulation… The PK analysis further showed that the blood levels of the intranasally administered active drug were substantially lower on average than what would ordinarily be expected with other routes of…

WednesdaySep 21, 2022 12:12 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Collaborates with EVERSANA(R) to Bring BEATdiabetes Solution to Market

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search